Compare CASS & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | RGNX |
|---|---|---|
| Founded | 1906 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.9M | 793.5M |
| IPO Year | 1996 | 2015 |
| Metric | CASS | RGNX |
|---|---|---|
| Price | $55.47 | $8.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $45.00 | $28.75 |
| AVG Volume (30 Days) | 64.7K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | 18.08 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $190,750,000.00 | $10,393,000.00 |
| Revenue This Year | $0.81 | $51.21 |
| Revenue Next Year | $4.39 | $19.08 |
| P/E Ratio | $37.38 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $36.07 | $5.46 |
| 52 Week High | $59.63 | $16.19 |
| Indicator | CASS | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 33.82 |
| Support Level | $51.22 | $5.67 |
| Resistance Level | $59.63 | $11.43 |
| Average True Range (ATR) | 1.14 | 0.47 |
| MACD | -0.19 | -0.12 |
| Stochastic Oscillator | 24.76 | 5.04 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.